local_hospital

Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki W Krakowie

Address
lock Available on a paid plan

Ophthalmology and Eye Diseases

At Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie, the ophthalmology department is active in trials focused on diabetic macular edema, age-related macular degeneration, uveitic macular edema, and thyroid eye disease. These studies are designed to evaluate new treatments and compare them with current care, with the goal of improving vision and slowing disease progression.

  • Testing new therapies for retinal and inflammatory eye conditions
  • Evaluating treatments for vision loss in diabetic eye disease
  • Studying options for thyroid eye disease and related orbital inflammation

The site’s strong eye-disease focus reflects its clinical specialization in both ophthalmology and ocular oncology.

Oncology and Hematologic Malignancies

Many trials at this hospital investigate cancers of the blood and solid tumors, including breast cancer, lymphoma, acute myeloid leukemia, multiple myeloma, prostate cancer, and gastrointestinal cancers. The research mainly aims to improve treatment effectiveness, extend survival, and find better options for patients with advanced or relapsed disease.

  • Assessing novel combinations for breast cancer, including hormone receptor-positive and triple-negative disease
  • Studying therapies for lymphoma, myelofibrosis, and other hematologic malignancies
  • Evaluating treatment strategies for advanced gastrointestinal, liver, ovarian, and urothelial cancers

Overall, the oncology portfolio is broad and includes both targeted treatments and immune-based approaches across multiple cancer types.

Cardiovascular, Stroke, and Metabolic Diseases

Clinical research in cardiovascular diseases includes heart failure, atrial fibrillation, myocardial infarction, hypertension, and stroke prevention. Additional studies address diabetes mellitus, chronic kidney disease, and other metabolic problems, with a focus on better control of risk and prevention of serious complications.

  • Testing approaches to reduce stroke risk in people with atrial fibrillation or after recent ischemic events
  • Evaluating treatments for heart failure and blood pressure that remains difficult to control
  • Studying therapies for type 2 diabetes and related metabolic disorders

These trials show a clear interest in preventing cardiovascular events while also addressing common chronic comorbidities.

Neurology and Autoimmune Disorders

The site also conducts research in neurological diseases and immune-mediated conditions, including multiple sclerosis, myasthenia gravis, epilepsy, autoimmune encephalitis, and amyotrophic lateral sclerosis. These studies are aimed at improving symptom control, reducing disease activity, and finding safer long-term treatment options.

  • Exploring therapies for relapsing and progressive multiple sclerosis
  • Evaluating treatments for myasthenia gravis and other neuromuscular disorders
  • Studying seizure control in refractory epilepsy and emergency seizure conditions

This area combines neurology with immunology, reflecting a strong interest in disorders driven by immune dysfunction.

Endocrinology, Rare Diseases, and Immune System Disorders

Research here extends to hormonal diseases, genetic conditions, and rare immune disorders such as congenital adrenal hyperplasia, hypoparathyroidism, hereditary angioedema, and Niemann-Pick disease type C1. The purpose of these trials is often to improve disease control, reduce symptoms, and better understand long-term safety and effectiveness of emerging therapies.

  • Studying treatment options for rare endocrine disorders and calcium regulation problems
  • Evaluating new approaches for hereditary angioedema and other complement-related diseases
  • Investigating therapies for inherited metabolic and genetic diseases

These trials highlight the site’s involvement in specialized research for patients with uncommon and often complex conditions.

Site Overview

assignment
248
connected trials
corporate_fare
124
sponsors
science
362
IMPs

Activity Indicator

Last 6 months

32
Trials started
+60% vs previous period.
20
Trials started 6–12 months ago
248
Total trials linked
Highly Active
trending_upGrowing+60%
5
4
6
12
4
1
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 5 of 20 therapeutic areas and 15 of 362 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 350 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
114
Sponsors (total)
124
Active sponsors
78

Sponsor Network

Top 78 by active trials.

lock +77 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +35 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 1 624 other sites in Poland

description
Trial volume
248
Outperforms 100% of sites
public
Therapeutic diversity
21areas
Outperforms 100% of sites
groups
Sponsor diversity
124sponsors
Outperforms 100% of sites

Therapeutic Area Benchmark — Poland

Select a therapeutic area to compare against other sites in Poland.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Poland

Market Share

Country: Poland

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki W Krakowie

lock Showing 1 of 248 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A 2-Part, Multicenter, Randomized, Blinded, Active-Controlled Phase 2 Study to Sequentially Evaluate the Safety and Efficacy of BIIB091 Monotherapy and BIIB091 Combination Therapy With Diroximel Fumarate in Participants With Relapsing Forms of Multiple SclerosisBiogen Idec Research LimitedPhase IINot RecruitingOct 2023Feb 2026

IMP list

lock Showing 1 of 362 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Infliximab11Unknown2018-11-302026-07-15

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.